Últimos Artículos de Diabetes, Obesity and Metabolism
- Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
- The effect of curcumin on hepatic fat content in individuals with obesity
- Long‐term clinical outcomes of oral antidiabetic drugs as fixed‐dose combinations: A nationwide retrospective cohort study
- Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study
- Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial
- Low‐dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity‐related chronic kidney disease
- Prognostic value of 24‐hour ambulatory blood pressure patterns in diabetes: A 21‐year longitudinal study
- Hospital costs associated with adverse events in people with diabetes in the UK
- Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies
- Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
- Effectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management
- Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open‐label, randomized controlled BEYOND‐V trial
- Glucagon‐like peptide‐1 effect on β‐cell function varies according to diabetes remission status after Roux‐en‐Y gastric bypass
- C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective
- Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
- Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan‐L‐CN randomized controlled trial
- Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis
- Forecasting postbariatric hypoglycaemia in patients after Roux‐en‐Y gastric bypass using model‐based algorithms fed by continuous glucose monitoring data: A proof‐of‐concept study
- The Association of Long‐Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population‐Based Cohort Study
- Acute concomitant glucose‐dependent insulinotropic polypeptide receptor antagonism during glucagon‐like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity